M

Massimo Massaia

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino

ORCID: 0000-0002-0021-1428

349 papers and 7.7k citations.

PubIndex Score70Top 30% · seniorHow it's scored

349Publications

7.7kTotal Citations

First publication: 1982First senior author: 1987

Top publicationsby citations

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Francesco Passamonti, Celestino Ferrandina, Carlo Gambacorti‐Passerini et al.|The Lancet Haematology|2020

Cited by 553

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia

Davide Rossi, Gianluca Gaïdano, Lodovico Terzi-di-Bergamo et al.|Blood|2015

Cited by 215

Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia

Davide Rossi, Marco Ladetto, Chiara Lobetti Bodoni et al.|Leukemia|2009

Cited by 98

The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells

Barbara Castella, Massimo Massaia|Nature Communications|2017

Cited by 72

Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter’s Syndrome Transformation in Chronic Lymphocytic Leukemia.

Davide Rossi, Marco Ladetto, Chiara Lobetti Bodoni et al.|Blood|2008

Cited by 1

Indexing the rest of 349 publications…